Skip to main content

Lynx Extends Service Contract with DuPont

NEW YORK, Nov. 11 (GenomeWeb News) - Lynx Therapeutics said today that it has signed a multi-year, multi-million dollar services agreement with DuPont that extends a five-year agreement the companies initiated in 1998.

Under the extended arrangement, DuPont and its subsidiary, Pioneer Hi-Bred International, will continue using Lynx's Massively Parallel Signature Sequencing (MPSS) technology for the discovery and development of new agricultural traits and products.

Financial details were not disclosed.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.